Personalised therapy reduces cancer risk for diabetes patients

November 8, 2016, Medical University of Vienna
Personalised therapy reduces cancer risk for diabetes patients
Personalised therapy reduces cancer risk for diabetes patients. Credit: Medical University of Vienna

The links between Type 2 diabetes and cancer are complex: people suffering from diabetes mellitus essentially have a higher risk of developing cancer but, on top of that, some diabetes drugs are also suspected of increasing the risk in some cases. However, scientists at the Department of Medicine III and the Section for Science of Complex Systems at MedUni Vienna have demonstrated that these risks can now be practically eliminated by using optimised, personalised therapy.

"Cancer and share common risk factors such as being overweight, smoking, poor eating habits, lack of exercise, insulin resistance, inflammatory and hormonal changes and, on top of that, poorly controlled diabetes with levels can increase the cancer risk," explains Alexandra Kautzky-Willer, MedUni Vienna expert in gender medicine and diabetes. A total of around 600,000 Austrians suffer from (Type 2 diabetes).

In a study published in the renowned Journal of Internal Medicine, Stefan Thurner and Peter Klimek from the Section for Science of Complex Systems and Kautzky-Willer were able to show that the risk can be eliminated using targeted precision medicine. And also that concomitant treatment with statins (which are mainly used to reduce cholesterol in metabolic disorders) are even associated with a reduced cancer risk and that the commonest and most widely used , metformin, displays consistently reduced risks – that also applies to the insulin sensitiser "pioglitazone" used in drug treatment to increase insulin sensitivity and hence counteract

The research setting: A statistical survey was compiled of 1.85 million Austrians who had been in hospital at least once. Around 300,000 of these had Type 2 diabetes – they were treated with a total of around 300 different combinations of diabetes drugs (incretin-based therapies and SGLT-2 inhibitors were not yet involved at this time). The results of the study: Primary insulin-stimulating drugs (sulphonylurea and insulin), displayed a significantly higher cancer risk than insulin inhibitors, especially in the case of pancreatic cancer in men and women, liver cancer in men and lymphoma in women – and this effect was significant in both men and women. "However, if statins are taken at the same time, this risk is massively reduced, even down to zero as compared with non-diabetic patients," says Kautzky-Willer.

"This shows that it is possible to optimise individual treatments to substantially reduce the general for diabetes patients. In today's precision medicine, we have a wide selection of drugs available to us and possible combination treatments that would make this possible," adds Klimek.

Explore further: Statins offset insulin-related cancer risk in T2DM

More information: A. Kautzky-Willer et al. Use of statins offsets insulin-related cancer risk, Journal of Internal Medicine (2016). DOI: 10.1111/joim.12567

Related Stories

Statins offset insulin-related cancer risk in T2DM

October 26, 2016
(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), use of statins offsets insulin-related cancer risks, according to research published online Oct. 21 in the Journal of Internal Medicine.

Gender of growing importance in diabetes studies

July 20, 2016
The international guidelines for the management of type 2 diabetes consider such factors such as age, social environment, the duration of the illness and associated health complaints. But gender is not included. This is becoming ...

Drug combination could help reduce risk of death in type 2 diabetes

May 5, 2016
People with type 2 diabetes treated with insulin plus metformin had a reduced risk of death and major cardiac events compared with people treated with insulin alone, a new study by Cardiff University shows.

Women are more prone to hypoglycaemia than men

June 27, 2012
Just how important a gender-specific perspective and the personalised treatment of illnesses are between men and women is being demonstrated by two current studies at the MedUni Vienna, which are being led by Alexandra Kautzky-Willer ...

Gender-based differences in glycemic control in T2DM

May 26, 2015
(HealthDay)—For patients with type 2 diabetes, there are gender-based differences in glycemic control and hypoglycemia after insulin treatment, according to research published in the June issue of Diabetes, Obesity and ...

Obesity increases risk of developing cancer

May 12, 2015
Cancer is more likely to develop in people who are very overweight (obese), because surplus body fat interferes with various hormone cycles and with glucose and fat metabolism. On the occasion of European Obesity Day this ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Thirty-year study shows women who breastfeed for six months or more reduce their diabetes risk

January 16, 2018
In a long-term national study, breastfeeding for six months or longer cuts the risk of developing type 2 diabetes nearly in half for women throughout their childbearing years, according to new Kaiser Permanente research published ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.